Stock FGEN FIBROGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages FibroGen, Inc.

Equities

FGEN

US31572Q8087

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-16 pm EDT 		5-day change 1st Jan Change
1.14 USD +7.55% Intraday chart for FibroGen, Inc. +35.86% +28.62%
Jul. 01 FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell Small Cap Comp Value Index CI
Jul. 01 FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell Small Cap Completeness Index CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Top Premarket Gainers
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier
FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting
Top Premarket Gainers
FibroGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting
Faron Pharmaceuticals reappoints former finance chief on interim basis
Top Midday Decliners
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
Sector Update: Health Care Stocks Rise Late Afternoon
Sector Update: Health Care Stocks Higher in Afternoon Trading
FibroGen Shares Jump After CEO Stock Purchase
FibroGen Names Deyaa Adib Chief Medical Officer
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer
FibroGen regains rights to anemia drug from AstraZeneca
FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
FibroGen, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
FibroGen, Inc. Regains All Rights to Roxadustat from Astrazeneca in the United States and Other Astrazeneca Territories, Except China and South Korea
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FGEN Stock
  4. News FibroGen, Inc.
  5. Other languages